Intuitive Surgical (NASDAQ:ISRG) Sets New 1-Year High – Here’s Why

Intuitive Surgical, Inc. (NASDAQ:ISRG) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $598.95 and last traded at $601.84, with a volume of 4133 shares trading hands. The stock had previously closed at $592.64.

Analyst Ratings Changes

Several brokerages have recently commented on ISRG. Truist Financial increased their price target on shares of Intuitive Surgical from $570.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Erste Group Bank upgraded Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Tuesday, November 19th. Mizuho boosted their price target on Intuitive Surgical from $440.00 to $500.00 in a research report on Thursday, October 17th. Wells Fargo & Company increased their price objective on Intuitive Surgical from $549.00 to $630.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. boosted their target price on Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $554.17.

Intuitive Surgical Price Performance

The firm has a 50 day moving average of $543.14 and a 200-day moving average of $501.89. The stock has a market capitalization of $217.43 billion, a P/E ratio of 98.14, a price-to-earnings-growth ratio of 5.13 and a beta of 1.39.

Insider Activity at Intuitive Surgical

In related news, CFO Jamie Samath sold 270 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $540.15, for a total value of $145,840.50. Following the sale, the chief financial officer now owns 8,757 shares of the company’s stock, valued at $4,730,093.55. The trade was a 2.99 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Robert Desantis sold 188 shares of the stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $506.52, for a total value of $95,225.76. Following the transaction, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,788,899.12. This represents a 3.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 43,487 shares of company stock worth $22,590,975. 0.90% of the stock is owned by corporate insiders.

Institutional Trading of Intuitive Surgical

Several large investors have recently added to or reduced their stakes in ISRG. Berbice Capital Management LLC acquired a new stake in Intuitive Surgical during the 4th quarter valued at $26,000. Godsey & Gibb Inc. increased its stake in shares of Intuitive Surgical by 140.0% in the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 35 shares in the last quarter. MidAtlantic Capital Management Inc. bought a new position in shares of Intuitive Surgical in the third quarter valued at about $33,000. Decker Retirement Planning Inc. acquired a new position in Intuitive Surgical during the 4th quarter worth about $36,000. Finally, Capital Performance Advisors LLP bought a new stake in Intuitive Surgical during the 3rd quarter worth about $38,000. 83.64% of the stock is owned by institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.